Metalloprotease (ADAM12-S) as a Predictor of Preeclampsia: Correlation with Severity, Maternal Complications, Fetal Outcome, and Doppler Parameters

REFERENCES

• Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308(5728):1592–1594.
   PubMed Web of Science ®Google Scholar
• Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365(9461):785–799.
   PubMed Web of Science ®Google Scholar
• Kinzler WL, Vintzileos AM. Fetal growth restriction: A modern approach. Curr Opin Obstet Gynecol 2008; 20(2):125–131.
   Google Scholar
• vonDadelszen P, Magee L. What matters in preeclampsia are the associated adverse outcomes: The view from Canada. Curr Opin Obstet Gynecol 2008; 20(2):110–115.
   Google Scholar
• Chen Q, Jones D, Stone P, Ching LM, Chamley L. Vitamin C enhances phagocytosis of necrotic trophoblasts by endothelial cells and protects the phagocytosing endothelial cells from activation. Placenta 2009; 30(2):163–168.
   Google Scholar
• Wolfsberg TG, Straight PD, Gerena RL, . ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain. Dev Biol 1995; 169(1):378–383.
   PubMed Web of Science ®Google Scholar
• Mino N, Miyahara R, Nakayama E, . A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma. J Surg Oncol 2009; 100(3):267–272.
   Google Scholar
• Markowski J, Tyszkiewicz T, Jarzab M, . Metal-proteinase ADAM12, kinesin 14 and checkpoint suppressor 1 as new molecular markers of laryngeal carcinoma. Eur Arch Otorhinolaryngol 2009; 266(10):1501–1507.
   Google Scholar
• Dyczynska E, Syta E, Sun D, Zolkiewska A. Breast cancer-associated mutations in metalloproteasedisintegrin ADAM12 interfere with the intracellular trafficking and processing of the protein. Int J Cancer 2008; 122(11):2634–2640.
   Google Scholar
• Fröhlich C, Albrechtsen R, Dyrskjøt L, Rudkjaer L, Ørntoft TF, Wewer UM. Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res 2006; 12(24):7359–7368.
   Google Scholar
• Peduto L, Reuter VE, Sehara-Fujisawa A, Shaffer DR, Scher HI, Blobel CP. ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression. Oncogene 2006; 25(39):5462–5466.
   PubMed Web of Science ®Google Scholar
• Farkas N, Lendeckel U, Dobrowolny H, . Reduced density of ADAM 12-immunoreactive oligodendrocytes in the anterior cingulate white matter of patients with schizophrenia. World J Biol Psychiatry 2010; 11(3):556–566.
   PubMed Web of Science ®Google Scholar
• Wang M, Lu S, Zhu Y, Li H. ADAM12 is an effective marker in the second trimester of pregnancy for prenatal screening of Down syndrome. Prenat Diagn 2010; 30(6):561–564.
   Google Scholar
• Wewer UM, Morgelin M, Holck P, . ADAM12 is a four-leafed clover: The excised prodomain remains bound to the mature enzyme. J Biol Chem 2006; 281(14):9418–9422.
   Google Scholar
• Laigaard J, Sørensen T, Fröhlich C, . ADAM12: A novel first trimester maternal serum marker for Down’s syndrome. Prenat Diagn 2003; 23(13):1086–1091.
   PubMed Web of Science ®Google Scholar
• ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. No. 33, January 2002. American College of Obstetricians and Gynecologists. Obstet Gynecol 2002; 99(1):159–167.
   PubMed Web of Science ®Google Scholar
• Shi Z, Xu W, Loechel F, Wewer UM, Murphy LJ. ADAM12, a disintegrin and metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 2000; 275(24):18574–18580.
   PubMed Web of Science ®Google Scholar
• Laigaard J, Christiansen M, Fröhlich C, Pedersen BN, Ottesen B, Wewer UM. The level of ADAM12-S in maternal serum is an early first-trimester marker of fetal trisomy 18. Prenat Diagn 2005; 25(1):45–46.
   Google Scholar
• Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspect Med 2008; 29(5):258–289.
   PubMed Web of Science ®Google Scholar
• Ito N, Nomura S, Iwase A, . ADAMs, a disintegrin and metalloproteinases, mediate shedding of oxytocinase. Biochem Biophys Res Commun 2004; 314(4):1008–1013.
   Google Scholar
• Santillan I, Markert UR, Fitzgerald JS. Expression of ADAM-12 in the human placenta. J Reprod Immunol 2010; 86(1):63.
   Google Scholar
• Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R, Wewer UM. A novel, secreted form of human ADAM 12 (meltrin α) provokes myogenesis in vivo. J Biol Chem 1998; 273(1):157–166.
   Google Scholar
• Laigaard J, Sørensen T, Placing S, . Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstet Gynecol 2005; 106(1):144–149.
   PubMed Web of Science ®Google Scholar
• Spencer K, Cowans NJ, Stamatopoulou A. ADAM12s in maternal serum as a potential marker of preeclampsia. Prenat Diagn 2008; 28(3):212–216.
   Google Scholar
• Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH. First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome. Obstet Gynecol 2008; 112(5):1082–1090.
   Google Scholar
• El-Sherbiny W, Soliman A, El-Mazny A. Elevated serum-soluble Fas in preeclampsia: Correlation with clinical, laboratory, and Doppler parameters. Hypertens Pregnancy 2011; 30(2):221–230.
   PubMed Web of Science ®Google Scholar
• Özeren M, Dinç H, Ekmen Ü, Senekayli C, Aydemir V. Umbilical and middle cerebral artery Doppler indices in patients with preeclampsia. Eur J Obstet Gynecol Reprod Biol 1999; 82(1):11–16.
   Google Scholar
• Pihl K, Larsen T, Krebs L, Christiansen M. First trimester maternal serum PAPP-A, beta-hCG and ADAM12 in prediction of small-for-gestational-age fetuses. Prenat Diagn 2008; 28(12):1131–1135.
   Google Scholar
• Cowans NJ, Spencer K. First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn 2007; 27(3):264–271.
   PubMed Web of Science ®Google Scholar